Log In


Voice of the Heart

We are a med-tech company made up of experienced personnel with over 200 years of combined expertise in cardiology and medical devices. We are currently underway with testing and manufacturing our insertable cardiac monitor device, and are backed by major investors, such as Sand Hill Angels. Future Cardia is currently in its pre-revenue stage of business development and focusing on R&D.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$1,677,211.94 Raised


200 years of combined expertise with multiple exits and two IPO

$8M previously raised by notable angel investor group and equity crowdfunding

A Stanford StartX company, a member of Johnson and Johnson's JLABS

the pitch

We are Future Cardia (Oracle Health, Inc.) - Bringing you a tiny insertable cardiac monitor for a long-term heart failure monitoring solution to disrupt the $5B market and to set the stage for Connected Implants. Our approach is a simple 2-minute office procedure that brings simplicity, accuracy, high compliance for long-term monitoring, and existing insurance coverage. We are actively testing and manufacturing our products, and are part of programs like Stanford StartX and Johnson & Johnson JLabs. We are backed by strong investors like Sand Hill Angels, and have previously raised $8 million.


Cardiologists and Patients Deserve a Better Option

Patients and Cardiologists lack viable monitoring solutions for Heart Failure. 

Future Cardia is designed to provide comprehensive long term data and analysis to doctors, Future Cardia also aims to build the largest collection of long-term cardiac data to improve the lives of patients. 

  • Detects early signs of Heart Failure problems before symptoms
  • Pre-clinical testing with 26 heart failure patients
  • Pre-clinical Lab Implants at Duke University
  • World Renown physicians from Harvard, Stanford, The OSU, and Maastricht joined
  • Using ECG and Heart Sounds as biomarkers for patients suffering from long-term cardiac diseases.


Heart Failure Emergencies are a $40 Billion a Year Problem*

A lack of remote Heart Failure monitoring solutions makes it difficult for heart failure patients and healthcare providers to address emergencies. As a chronic disease, our patients and physicians are stuck between real emergencies and false alarms, resulting in referral to the Emergency Department and subsequent admission to the hospital, even if it is a false alarm.   


Heart failure is a cardiac condition that often results in breathing problems and frequent hospitalizations. Heart Failure patients have weakened heart muscle. As the heart begins to fail, fluid slowly accumulates in the lungs, which can lead to sudden and severe breathing problems.

In the US alone, six million patients suffer from Heart Failure. Canada and Europe are facing the same problem. Because of the lack of a remote monitoring solution for Heart Failure, patients are referred to the ER and subsequently hospitalized, even if it is a false alarm.

Invasive heart procedure devices such as CardioMems by Abbott are the current standard. This device requires a sensor implant inside the heart or around the heart (Pulmonary Artery) in a cath lab procedure. Accurate, however, they are expensive, complex and are not the ideal solution for all patients.

Wearable monitors are ideal for short-term solutions, however, they suffer from low accuracy, patient non-compliance, and limited data. Therefore, they have a limited use when it comes to long-term Heart Failure monitoring.


$5 Billion Total Addressable Market Opportunity

Initially, Future Cardia will focus on the one million patients suffering from heart failure, who are in immediate need of remote monitoring solutions. Eventually, we hope to reach all six million Americans who suffer from heart failure.


A Cardiac Monitor Using Remote Monitoring Technology and AI

Future Cardia is developing a tiny, insertable cardiac device to monitor Heart Failure and reduce unnecessary hospitalizations. The device utilizes multi-sensors, remote monitoring technology and cloud based Artificial Intelligence for long-term comprehensive cardiac monitoring. 

This is a simple 2-minute office procedure that does not require a follow up, saving time for both patients and cardiologists. The device is inserted under the skin for improved accuracy, and does not require invasive surgery that other implanted devices do.    

*Product images are computer-generated demo versions of a product currently under development. 

*The Company's smart phone app is currently in beta development and not currently available for general use.

By tracking trends in ECG and Heart Sounds readings, physicians can detect heart failure decompensation before the onset of symptoms. This gives them actionable data to steer the patient away from further complications.  

Billions of data points for a comprehensive long term cardiac monitoring solution

Future Cardia is developing a compact cardiac device that is inserted subcutaneously (under the skin) in a two-minute office procedure. Once administered, each device yields billions of data points, allowing healthcare providers to compare trending changes over 2-3 years for continuous cardiac monitoring. As Future Cardia collects more data, the analysis will improve through the use of machine learning and AI using ECG and Heart Sounds as biomarkers for Cardiology.


Our product relies on three main features: 

1. An ECG to record electrical activities of the heart

2. An acoustic sensor to listen to the heart and lung sounds, 

3. And an Accelerometer to record activity.

Our device has high patient compliance over the long-term, because patients do not need to follow a complex process to monitor their cardiac health.

Recorded cardiac data is securely transmitted to a smartphone, then to a cloud-based Artificial Intelligence algorithm for analysis, which the cardiologist can then review and take action.


By analyzing electrical and physiological trends, Future Cardia detects subtle changes and early signs of cardiac decline even before symptoms appear. This allows clinicians to prioritize at-risk patients, implement therapeutic interventions, and prevent hospitalizations. 


Short Regulatory Path with Existing Insurance Coverage of $7,600 / Device for Commercialization 

Future Cardia has a simple go-to-market plan. First, we will focus on two highest volume regions, Texas and Florida. We expect Texas and Florida to generate $5.5 million within two years of launch. Each unit will retail for $5,300/unit with an established reimbursement of $7,600 (insurance coverage). With this business model, we anticipate that our first 5K implants will generate $26M in revenue within approximately 4 years.

Second, we will obtain the most comprehensive, long-term cardiac data to date as biomarkers for cardiology. This will allow Future Cardia to venture into predictions for cardiac events, and human longevity study.  


910 Woodbridge Court
Safety Harbor, FL 34695

We are a med-tech company made up of experienced personnel with over 200 years of combined expertise in cardiology and medical devices. We are currently underway with testing and manufacturing our insertable cardiac monitor device, and are backed by major investors, such as Sand Hill Angels. Future Cardia is currently in its pre-revenue stage of business development and focusing on R&D.


Jaeson Bang
Jaeson Bang
CEO, Founder, Secretary, Treasurer, and Director

Heart Failure Clinical, Technology and Business operations for the past 18 years with Medtronic and Silicon Valley Startups.

-Extensive background in sales and product development in implantable devices operations.

-Kellogg MBA

Lauren Ioslavits

Lauren Ioslavits

Board Member

Lauren serves as a Board Member for Future Cardia.

Lauren is an entrepreneur and senior executive with over 25 years of experience delivering results. She is currently the CEO of Meel Corp., a producer and distributor of frozen foods to the retail, club and food service channels. Prior to Meel Corp., Lauren was the co-founder of Investran, the Private Equity industry’s leading platform for fund administration and investor reporting. She was also part of the founding team of TM1 which, through a series of M&A transactions, is now the centerpiece of IBM’s Planning and Analytics platform.

Lauren is a seed investor in investment technology platforms and serves as a strategic advisor and board member to several of them.

Randy Brase

Randy Brase

VP of Manufacturing

-Over 30 years of medical device design and manufacturing expertise with Medtronic, Boston Scientific and ImThera

John Kruse

John Kruse

VP of R&D and Electrical Engineer

-Over 40 years of medical device design, and R&D with Medtronic and Analog Devices

John Melquist

John Melquist

VP of Quality Assurance

-Over 40 years of expertise in QA with Medtronic and Allen Welch.

Dimitrios Georgakopoulos PhD

Dimitrios Georgakopoulos PhD

Scientific Advisor

Heart Failure and Cardiac Hemodynamics scientist at Startups and a NASDAQ company.

Held Chief Science Officer position at a NASDAQ company.

PhD from Johns Hopkins

Dr. Dan Burkhoff MD PhD

Dr. Dan Burkhoff MD PhD

Medical Advisor

World renowned Physician Scientist with med tech startup and Heart Failure expertise.

Multiple exits. 

Served at a VP at Heartware, which was acquired by Medtronic for $1.2B.

Dr. Kevin Heist MD PhD

Dr. Kevin Heist MD PhD

Medical Advisor

Stanford MD PhD, currently at Harvard.

Cardiologist with his specialty in the field of Electrophysiology to treat Cardiac Arrhythmias. 

Currently practicing at Mass General Hospital in Boston.

Anatoly Yakovlev PhD

Anatoly Yakovlev PhD

Machine Learning Advisor

Stanford PhD with expertise in neuromodulations and AI.

Electrical Engineering and PhD from Stanford University. 

Currently working on AI at a top software company in Silicon Valley.

Professor Frits Prinzen PhD

Professor Frits Prinzen PhD

Scientific Advisor

World's foremost expert in Cardiac Mechanics and Hemodynamics scientist.

Architect of commonly used cardiac models and publisher of landmark research.

Dr. Toshi Okabe MD

Dr. Toshi Okabe MD

Medical Advisor

Electrophysiology Cardiologist from Ohio State University.

Expertise in managing cardiac arrhythmia and cardiac ablations.

Dr. David Kraus MD

Dr. David Kraus MD

Medical Advisor

Heart Failure and Cardiac Transplant Physician.

Top clinical trialist in the US.


Future Cardia
Oct 31, 2023
$10k - $5M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives & Bonuses*

Loyalty Bonus | 10% Bonus Shares

Previous Investors in Future Cardia will receive additional 10% bonus shares.


Friends and Family Early Birds

Invest within the first 72 hours and receive 20% bonus shares.

Super Early Bird Bonus

Invest within the first week and receive 15% bonus shares.

Early Bird Bonus

 Invest within the first two weeks and receive 10% bonus shares


$1,000+ | Tier 1

Receive 5% bonus shares.

$2,500+ | Tier 2

Receive 7% bonus shares.

$5,000+ |Tier 3

Receive 10% bonus shares.

$10,000+ | Tier 4

Receive 15% bonus shares.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Future Cardia, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.95 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $295. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and Loyalty Bonus in addition to the aforementioned bonus.


Article Image

YCombinator Drop-Out, Future Cardia, Raises $5M to Challenge the Biggest MedTech Corporations in the World


Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Future Cardia.


Earn 10% Bonus Shares

Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.


Tier 1

Receive 5% bonus shares.


Tier 2

Receive 7% bonus shares.


Tier 3

Receive 10% bonus shares.


Tier 4

Receive 15% bonus shares.



Daniel Devlin

a month ago

Hi Jaeson, congratulations on all your progress so far. I am interested in investing but have a few questions. Thank you in advance for your responses! 1) Can you provide more info on the upcoming human trials? E.g. projected start date, location, # of participants, when you’re expecting to start seeing results, etc. 2) In your go-to-market you mention targeting 6 hospitals and 20 doctors in Florida/Texas. What made you choose these targets and are they all contacts you’ve had early sales discussions with? What is the current feedback you’re getting? 3) What made you select “Diastolic Heart Failure with Arrhythmia indications” as your initial target? I love the specificity but am curious as to the reasoning. 4) If I understand correctly, you’ve raised ~$2.5M from accredited investors (not crowdfunding) at various valuations. Do these investors have preferred or common stock? Are any participating again in this round? Thank you!



Chan Komagan

a month ago

We haven't received any update for a couple of months. If would be nice if the management provides us some progress updates.



hendrik brower

2 months ago

Are their patents or pending applications that will secure your position? What are the most significant barriers that other companies will face if your product is successful?



Masika Weeks

3 months ago

whats the passcode for the webinar?



Jahana Chittakath

3 months ago

Hi, Can I consider this as a Islamic sharia based investment



Gary Lockwood

3 months ago

How is this device powered? And how long after implantation will it need recharged?



Cody Heisinger

3 months ago

Does the previous crowdfunded amount include rounds raised under Oracle Health? Why the change?



Viral Kothary

3 months ago

Hi Jaeson- I have invested twice and looking to do a third time before it closes. A few questions: 1) how many more rounds of funding are you planning on applying for (through any source)? In essence, how diluted will my shares become? 2) what is the status on your patents? 3) do your patents affect the products already available by Boston Scientific and Medtronic? Both companies are much larger and better incorporated into the current medical market. 4) is the plan to keep Future Cardia as a viable company that produces and provides products, Or to be bought out by one of the larger companies? 5) how close are you (when will you be starting) human trials in the real world? Thanks!



Adam Forster

3 months ago

Jaeson, Can you review the procedures and tests that are done to make sure the device works, that what the device measures is properly recorded and tracked and that it will not adversely affect the patient? It is exciting to be approaching the first human implant - just thinking of things that could go right or wrong and how you have worked to make sure that things go right. Also thinking of adding to prior investments. Best, Adam




3 months ago

The LUMA webinar system does not work, nothing registers




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from www.startengine.com (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.